Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria: * All patients will have ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the World Federation of Neurology criteria for the diagnosis of ALS. * Examination and neurophysiological testing confirm a pure motor syndrome compatible with the diagnosis of ALS. All other possible causes of weakness have been excluded by extensive investigations. * Age greater than 18 years, if female, must be post-menopausal, had a hysterectomy, or agree to two forms of birth control. * Permanent resident or citizen of the United States. * Geographic accessibility to the study site and willingness and ability to comply with follow-up. * History of a chronic onset of a progressive motor weakness of less than two years duration. * Subjects must be taking a stable dose of riluzole for at least 30 days prior to enrolment or not be on riluzole, and not have been on it for at least 30 days prior to enrolment (riluzole-naïve subjects are permitted in the study). * Subjects must be taking a stable dose of oral Radicava® (edaravone) for at least 30 days prior to enrolment or not be on oral Radicava® (edaravone), and not have been on it for at least 30 days prior to enrolment (edaravone-naïve subjects are permitted in the study). * Able to comply with protocol requirements, including MRI testing. * Can provide written informed consent. Exclusion Criteria: * Use of Radicava® (edaravone) within 30 days of screening or intent to use Radicava® a…